Cingulate Inc.

Cingulate Inc. (CING) priced its initial public offering on Dec 9, 2021 at $6.00 per share, raising $25M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $67.9M. Aegis Capital was lead-left underwriter, joined by Laidlaw. Lowenstein Sandler advised the company and Sichenzia Ross Ference Carmel advised the underwriters.

Cingulate Inc. is a clinical-stage biopharmaceutical company using its Precision Timed Release drug delivery platform to develop next-generation medicines that reduce burdensome daily dosing. It is initially focused on treating attention deficit/hyperactivity disorder (ADHD).

Status

IPO

Ticker

CING

Exchange

Nasdaq Capital Market

Priced

Dec 9, 2021

IPO price

$6.00

Raised

$25M

Market cap at IPO price

$67.9M

First filed

Sep 9, 2021

Underwriters

Aegis Capital and Laidlaw

Company counsel

Lowenstein Sandler

Underwriters' counsel

Sichenzia Ross Ference Carmel

Sector

Biotech & pharma

Country / state

KS

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.